ClinicalTrials.gg
CompletedNCT07844356Updated Sep 28, 2026

The Safety and Efficacy of HR19034 in Children With Myopia

A Phase 2/3 interventional study of HR19034 and HR19034 in Slowing the Progression of Myopia in Children, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years 11 months after the study started (first participant enrolled Oct 2021, registered Sep 2026).
Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
509
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 221 studies in Myopia with a site in China — 79 open to participants now, 101 under way, 4 of them phase 3. Myopia · China.

Enrollment
24th of 155
509 · median 150
Started
2021
with 15 others
Phase 2/3
Only one
of the 221
Registered
217th of 221
by date

Among the 221 studies in Myopia with a site in China, this one is the 24th largest by enrollment of the 155 interventional ones that give a count, is one of 16 that started in 2021, is the only one in phase 2/3, and was the 217th registered.

Myopia

1,165 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

79 of the 221 studies in Myopia with a site in China are open now. Recruiting first, the newest first:

74 more — sign in →

All 79 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 123 Myopia studies recruiting now, 19 (15%) set no upper age limit and 103 (84%) stop at 75 or younger; 85 take children under 18; 52 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 221 studies in Myopia with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, and safety of HR19034 Eye Drops. To explore the reasonable dosage of HR19034 for slowing the progression of myopia in children

03

Conditions studied

  • Slowing the Progression of Myopia in Children

Browse trials for

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged ≥6 and \<12 years at the time of .
  2. Refractive status meets the following conditions:

    a) Myopia of 0.5 D (diopters) to 4.00 D (inclusive) in both eyes; B) Astigmatism ≤1.50 D in both eyes; c) Anisometropia ≤1.5 D;

  3. Intraocular pressure ≤21 mmHg;
  4. The best corrected distance visual acuity of both eyes of logMAR 0 or better;

Exclusion criteria

Exclusion Criteria:

  1. Allergy to the drug or any of its components.
  2. Any abnormality of the refractive system in either eye, including but not limited to keratoconus, lenticonus, or spherophakia.
  3. Systemic conditions that may affect refractive development or predispose to high myopia, such as Down syndrome, Marfan syndrome, retinopathy of prematurity, or neonatal hypoxic-ischemic encephalopathy.
  4. Any other ocular abnormality or disease affecting vision in either eye, including ptosis, congenital corneal abnormalities, corneal leukoma, congenital lens abnormalities, cataract, macular lesions, choroidal lesions, severe vitreous opacity, or retinal lesions.
  5. History of glaucoma and/or shallow anterior chamber in either eye.
  6. History or current presence of significant strabismus, amblyopia, or nystagmus.
  7. Prior eyelid surgery, strabismus surgery, intraocular surgery, or refractive surgery.
  8. Systemic or local use of medications that may affect efficacy evaluation within 3 months prior to screening, including anticholinergics (e.g., atropine, pirenzepine), cholinergics (e.g., pilocarpine), or drugs affecting pupil size or accommodation (e.g., Belladonna tablets, morphine, sedative-hypnotics). Exception: non-atropine mydriatics used solely for dilated eye examinations, provided they are not continuous, regular, or long-term use.
  9. Use of myopia control treatments within 1 month prior to screening, including atropine or other antimuscarinic agents, bifocal/progressive/multifocal contact lenses or spectacles, orthokeratology lenses, or rigid gas permeable contact lenses for myopia reduction.
  10. History or current presence of systemic diseases, including immune system disorders, central nervous system disorders, asthma, diabetes, severe cardiopulmonary dysfunction, or severe hepatic or renal dysfunction.
  11. Clear family history of high myopia.
  12. Participation in another interventional clinical trial within 3 months prior to randomization.
  13. Any other condition that, in the opinion of the investigator, would make the subject unsuitable for participation in this trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
509 participants (actual)

Study arms

  • Experimental
    Treatment group A: HR19034 Dose 1

    Drug: HR19034

  • Experimental
    Treatment group B: HR19034 Dose 2

    Drug: HR19034

  • Placebo comparator
    Treatment group C: Placebo

    Drug: Placebo

Interventions

  • DrugHR19034

    HR19034 Dose 1

  • DrugHR19034

    HR19034 Dose 2

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change from baseline in spherical equivalent refraction (SER) measured by cycloplegic autorefraction in the study eye

    Time frame: Baseline to Week 96

Secondary outcomes

  1. Change from baseline in spherical equivalent refraction (SER) in the fellow eye

    Time frame: Baseline to Week 96

  2. Change from baseline in axial length (AL) in the study eye and fellow eye

    Time frame: Baseline to Week 96

  3. Percentage of participants with progression in SER of more than 0.75 D in the study eye and fellow eye

    Time frame: Baseline to Week 96

  4. Percentage of participants with progression in SER of more than 0.50 D in the study eye and fellow eye

    Time frame: Baseline to Week 96

  5. Percentage of participants with progression in SER of more than 1.00 D in the study eye and fellow eye

    Time frame: Baseline to Week 96

  6. Change from baseline in vision-related quality of life

    Time frame: Baseline to Week 96

  7. Change from baseline in SER in the study eye and fellow eye

    Time frame: Baseline to Week 48

  8. Change from baseline in AL in the study eye and fellow eye

    Time frame: Baseline to Week 48

  9. Percentage of participants with progression in SER of more than 0.75 D, 0.50 D and 1.00 D in the study eye and fellow eye

    Time frame: Baseline to Week 48

  10. Change from baseline in vision-related quality of life

    Time frame: Baseline to Week 48

  11. Change from baseline/Week 96 in SER in the study eye and fellow eye

    Time frame: Baseline/Week 96 to Week 120 and 144

  12. Change from baseline/Week 96 in AL in the study eye and fellow eye

    Time frame: Baseline/Week 96 to Week 120 and 144

  13. Percentage of participants with progression in SER from Week 96 of more than 0.75 D in the study eye and fellow eye

    Time frame: Week 96 to Week 120 and 144]

07

Study locations

1 site
  • Xiamen Eye Center, Affiliated to Xiamen University
    Xiamen, Fujian 361016, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Aug 2024, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartActual
Oct 14, 2021
Primary completionActual
Aug 9, 2024
CompletionActual
Jul 25, 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844356
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Oct 14, 2021
Primary completion
Aug 9, 2024
Completion
Jul 25, 2025
Last update
Sep 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion